![Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial - Laffel - 2018 - Diabetic Medicine - Wiley Online Library Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial - Laffel - 2018 - Diabetic Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/f66554fd-6d5f-4df8-a88b-235e49e0bfbb/dme13629-fig-0001-m.jpg)
Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial - Laffel - 2018 - Diabetic Medicine - Wiley Online Library
![Cells | Free Full-Text | Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics Cells | Free Full-Text | Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics](https://pub.mdpi-res.com/cells/cells-11-03372/article_deploy/html/images/cells-11-03372-ag-550.jpg?1667973845)
Cells | Free Full-Text | Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics
![Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus | HKMJ Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus | HKMJ](https://www.hkmj.org/system/files/hkmj197802-table.jpg)
Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus | HKMJ
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
![Pharmaceutics | Free Full-Text | A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes Pharmaceutics | Free Full-Text | A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00485/article_deploy/html/images/pharmaceutics-13-00485-g001-550.jpg)